(Q38077311)

28 August 2017

Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

Rui Huang

1

1 reference

28 August 2017

Yingying Hao

series ordinal

2

1 reference

28 August 2017

Jun Zhang

series ordinal

3

1 reference

28 August 2017

Chao Wu

series ordinal

4

1 reference

28 August 2017

29 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

43

1 reference

28 August 2017

10

1 reference

28 August 2017

1040-1051

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

28 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Hepatitis B: reflections on the current approach to antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Monotherapy versus combination therapy for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Benefits and risks of combination therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12058

21 January 2018

Identifiers

DOI

10.1111/HEPR.12058

1 reference

28 August 2017

1 reference